CANC · NASDAQ · ETF
Tema Oncology ETF (CANC) Price, Holdings & Fees
Tema Oncology ETF (CANC) closed at $718.35 on Oct 9, 2026, up 0.36% from the previous close of $715.75.
Share price, past year
1Y +29.34%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $718.35 |
| Sep 30, 2026 | $710.50 |
| Aug 31, 2026 | $662.79 |
| Jul 31, 2026 | $636.04 |
| Jun 30, 2026 | $671.10 |
| May 29, 2026 | $686.38 |
| Apr 30, 2026 | $689.57 |
| Mar 31, 2026 | $622.38 |
| Feb 27, 2026 | $644.79 |
| Jan 30, 2026 | $707.78 |
| Dec 31, 2025 | $686.70 |
| Nov 28, 2025 | $649.18 |
| Oct 31, 2025 | $588.79 |
Key statistics
- Expense ratio
- 0.75%
- as of Jun 30, 2026
- Net assets
- $176.1M
- as of May 31, 2026
- Holdings
- 57
- as of May 31, 2026
- 52-week range
- $553.26 – $720.25
Tema Oncology ETF's expense ratio is 0.75%: $75.00 a year on $10,000 invested.
Holdings
Tema Oncology ETF held 57 investments worth $176.14M as of May 31, 2026. Its largest holding was Revolution Medicines Inc, at 7.73% of the fund.
| # | Holding | % of fund | Value |
|---|---|---|---|
| 1 | Revolution Medicines IncRVMD | 7.73% | $13.61M |
| 2 | Eli Lilly & CoLLY | 4.82% | $8.49M |
| 3 | Roche Holding AGRHHBY | 4.21% | $7.42M |
| 4 | Cogent Biosciences IncCOGT | 4.10% | $7.22M |
| 5 | Novartis AG | 4.03% | $9.09M |
| 6 | Immunome IncIMNM | 3.91% | $6.89M |
| 7 | Celcuity IncCELC | 3.58% | $6.31M |
| 8 | Merck & Co IncMRK | 3.57% | $6.29M |
| 9 | AstraZeneca PLCAZN | 3.54% | $8.39M |
| 10 | Nuvalent Inc | 3.37% | $5.93M |
| 11 | Bristol-Myers Squibb CoBMY | 3.30% | $5.81M |
| 12 | Legend Biotech CorpLEGN | 2.99% | $5.27M |
| 13 | AbbVie IncABBV | 2.81% | $4.94M |
| 14 | Exelixis IncEXEL | 2.78% | $4.89M |
| 15 | Bridgebio Pharma IncBBIO | 2.75% | $4.85M |
| 16 | Johnson & JohnsonJNJ | 2.55% | $4.48M |
| 17 | CG oncology IncCGON | 2.43% | $4.28M |
| 18 | Genmab A/SGMAB | 2.37% | $4.18M |
| 19 | Ideaya Biosciences IncIDYA | 2.27% | $4.00M |
| 20 | Amgen IncAMGN | 2.11% | $3.71M |
| 21 | Zai Lab LtdZLAB | 1.98% | $3.48M |
| 22 | BeOne Medicines LtdONC | 1.88% | $3.31M |
| 23 | Zymeworks IncZYME | 1.51% | $2.65M |
| 24 | Enliven Therapeutics IncELVN | 1.31% | $2.30M |
| 25 | Relay Therapeutics IncRLAY | 1.28% | $2.26M |
Top 25 of 57 holdings, as of May 31, 2026. Percentages are of the fund's net assets.
What the fund owns
| Asset type | % of fund |
|---|---|
| Stocks | 98.99% |
| Cash and short-term investments | 1.09% |
| Country | % of fund |
|---|---|
| United States | 80.91% |
| Switzerland | 8.24% |
| United Kingdom | 4.04% |
| Denmark | 2.37% |
| China | 1.98% |
| Germany | 1.12% |
| Japan | 0.67% |
| Hong Kong | 0.44% |
| Cayman Islands | 0.30% |
Shares of net assets from the fund's N-PORT report. Funds that borrow can add up to more than 100%, with borrowing (such as repurchase agreements) shown as a negative share.
Monthly total returns
Over the 3 months to May 31, 2026, Tema Oncology ETF's total return was +0.89%, as reported to the SEC.
| Month | Total return |
|---|---|
| May 31, 2026 | +1.52% |
| Apr 30, 2026 | +2.45% |
| Mar 31, 2026 | −3.00% |
The fund's own total returns as reported to the SEC (N-PORT), including reinvested distributions. Not the sample prices above.
Fund profile
- Name
- Tema Oncology ETF
- Ticker
- CANC
- Exchange
- NASDAQ
- Fund type
- ETF
- Trust
- Tema ETF Trust
- SEC series ID
- S000078299
- SEC CIK
- 0001944285
- Fractional shares
- No
Recent SEC filings
- Jul 29, 2026
- 485BPOSProspectus updateOct 5, 2026
- 485BPOSProspectus updateSep 8, 2026
- 485BPOSProspectus updateAug 17, 2026
- 485BPOSProspectus updateJul 14, 2026
- 485BPOSProspectus updateJun 29, 2026
- 485BPOSProspectus updateJun 29, 2026
- May 11, 2026
Shareholder reports and prospectuses are filed by Tema ETF Trust, the trust behind Tema Oncology ETF, and cover all of its funds.
Frequently asked questions
What is CANC's price?
Tema Oncology ETF (CANC) closed at $718.35 on Oct 9, 2026, up 0.36% from the previous close of $715.75.
What is CANC's expense ratio?
Tema Oncology ETF's expense ratio is 0.75%: $75.00 a year on $10,000 invested.
What does CANC hold?
Tema Oncology ETF held 57 investments worth $176.14M as of May 31, 2026. Its largest holding was Revolution Medicines Inc, at 7.73% of the fund. Its five largest holdings were Revolution Medicines Inc, Eli Lilly & Co, Roche Holding AG, Cogent Biosciences Inc, Novartis AG.
How has CANC performed?
Over the 3 months to May 31, 2026, Tema Oncology ETF's total return was +0.89%, as reported to the SEC.
Sources and methodology
Holdings, net assets and monthly returns come from the fund's N-PORT filing with the SEC, as of May 31, 2026 (filed Jul 29, 2026). The expense ratio is from the fund's prospectus or shareholder report, as of Jun 30, 2026. Prices are generated sample data for development. Data sources and disclosures